Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00476905 · ClinicalTrials.gov registry record

Spectral Diagnosis of Cutaneous Malignancy

A clinical trial, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
350
Enrollment target

NCT00476905: Completed study, sponsored by M.D. Anderson Cancer Center.

NCT00476905 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 350 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00476905 has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
350 participants
Enrollment target

Study Summary

The goal of this clinical research study is to evaluate the use of an imaging technology called spectral diagnosis. Researchers want to find out if a special spectral-diagnosis probe can be used to detect skin cancers.

Interventions

  • DEVICE Spectral Diagnosis Probe

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2007-04
Est. Completion 2018-11-20

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT00476905

The ClinicalTrials.gov registry entry for NCT00476905 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Spectral Diagnosis Probe is the first listed.

NCT00476905 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00476905 about?

NCT00476905 is a clinical study titled "Spectral Diagnosis of Cutaneous Malignancy". The goal of this clinical research study is to evaluate the use of an imaging technology called spectral diagnosis. Researchers want to find out if a special spectral-diagnosis probe can be used to detect skin cancers.

What is the current status of trial NCT00476905?

This trial is currently completed. The enrollment target is 350 participants. The study started on 2007-04. Estimated completion is 2018-11-20.

What interventions are being tested in trial NCT00476905?

The interventions under investigation include: Spectral Diagnosis Probe (DEVICE).

Who is sponsoring clinical trial NCT00476905?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.